WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 9:45 a.m. PT.
The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
Kandu, Inc. Announces $30 Million Financing to Advance Stroke Recovery and Rehabilitation VAN NUYS, Calif.--(BUSINESS…
Burlington, Ontario--(Newsfile Corp. - April 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or…
PHOENIX, April 08, 2025 (GLOBE NEWSWIRE) -- The healthcare industry has outgrown the outdated and…
New partnership strengthens Psyence BioMed's global clinical trial capabilities, accelerating the development of psilocybin-assisted therapy…
Strategic alliance set to strengthen supply chains for medical isotopes, industrial applications, and fusion technologies…
Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic…